Table of Contents Author Guidelines Submit a Manuscript
Journal of Skin Cancer
Volume 2015, Article ID 953479, 6 pages
Research Article

Comorbidity Assessment in Skin Cancer Patients: A Pilot Study Comparing Medical Interview with a Patient-Reported Questionnaire

1Department of Medicine, Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10022, USA
2Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
3Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA

Received 6 January 2015; Revised 21 May 2015; Accepted 24 May 2015

Academic Editor: Lionel Larue

Copyright © 2015 Erica H. Lee et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Background. Comorbidities are conditions that occur simultaneously but independently of another disorder. Among skin cancer patients, comorbidities are common and may influence management. Objective. We compared comorbidity assessment by traditional medical interview (MI) and by standardized patient-reported questionnaire based on the Adult Comorbidity Evaluation-27 (ACE-27). Methods. Between September 2011 and October 2013, skin cancer patients underwent prospective comorbidity assessment by a Mohs surgeon (MI) and a radiation oncologist (using a standardized patient-reported questionnaire based on the ACE-27, the PRACE-27). Comorbidities were identified and graded according to the ACE-27 and compared for agreement. Results. Forty-four patients were evaluated. MI and PRACE-27 identified comorbidities in 79.5% and 88.6% () of patients, respectively. Among 27 comorbid ailments, the MI identified 9.9% as being present, while the PRACE-27 identified 12.5%. When there were discordant observations, PRACE-27 was more likely than MI to identify the comorbidity (, 95% CI = 2.4–14.4, ). Overall comorbidity scores were moderate or severe in 43.2% (MI) versus 59.1% (PRACE-27) (). Limitations. Small sample size from a single institution. Conclusion. Comorbidities are common in skin cancer patients, and a standardized questionnaire may better identify and grade them. More accurate comorbidity assessments may help guide skin cancer management.